1. Home
  2. Press release
May 14, 2020 09:22 JST

Source: Eisai

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

TOKYO, May 14, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA , "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN , "eribulin") will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program(1)), from May 29 to 31, 2020.

At this year's meeting, the final results of two studies will be presented on the combination therapy of lenvatinib with the anti-PD-1 antibody KEYTRUDA (generic name: pembrolizumab, "pembrolizumab") from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada). One is the oral presentation of the metastatic renal cell carcinoma cohort (Abstract number: 5008) of Study 111 / KEYNOTE-146, and the other is the poster discussion presentation of the first-line therapy for unresectable hepatocellular carcinoma (Abstract number: 4519) in Study 116 / KEYNOTE-524(2).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) Presentation materials will be made available on demand via ASCO's website at 8:00 AM on May 29th (ET).
(2) This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
June 17 2026 12:28 JST
 
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
 
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
More Press release >>

Latest Press Release


Japantastics Introduces Sato Mokko to the World -- A New Chapter in Japanese Artisanal Craftsmanship
Jun 18, 2026 08:00 JST

Hitachi expands its work with OpenAI to accelerate AI-driven modernization and cybersecurity
Jun 17, 2026 14:54 JST

Fujitsu and IBM Japan collaborate on modernization to support enterprise digital transformation
Jun 17, 2026 14:23 JST

Sharp to Introduce AQUOS R11 Smartphone
Jun 17, 2026 13:59 JST

Honda to Begin Supplying Three High-output Models of the eGX Electric Power Unit Series for Commercial-Grade Work Equipment
Jun 17, 2026 13:44 JST

Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
Jun 17, 2026 13:28 JST

BAE Systems and NEC Sign MoU to Strengthen Japan's Active Cyber Defence
Jun 17, 2026 13:10 JST

Anime Tokyo Station Early Summer Festival
Jun 17, 2026 11:00 JST

Hitachi Energy expands zero-emission power portfolio with HyFlex Compact
Jun 13, 2026 00:06 JST

Hitachi Energy unveils AxoniQ: game-changing solution for the next era of transmission grids
Jun 12, 2026 23:42 JST

Team Mitsubishi Ralliart Confirms Triton Readiness as It Targets Second Consecutive AXCR Title
Jun 12, 2026 23:20 JST

Report verifying the net carbon impact of NEC's agricultural solution, CropScope, published as part of the Net Carbon Impact initiative promoted by the EU Green Digital Coalition
Jun 12, 2026 21:40 JST

NEC's Face Recognition Walkthrough Gate for JR East railways wins "Best of the Best" at the "Red Dot Design Award 2026"
Jun 12, 2026 13:29 JST

Mitsubishi Motors to Launch All-New Eclipse Sportback EV in the United States and Canada
Jun 10, 2026 23:15 JST

Bosch Home Comfort Group and Hitachi Group agree to collaborate on Intelligent connectivity and diagnosis solutions for Commercial Air Conditioning based on "HMAX for Buildings"
Jun 10, 2026 22:47 JST

Hitachi and Google Cloud expand strategic alliance to accelerate real-world deployment of physical AI through FDE and advanced cybersecurity solutions
Jun 10, 2026 22:18 JST

Toyota to participate in the "1000 Miglia Gran Turismo Experience 2026," a special program of the historic Italian rally, the 1000 Miglia
Jun 10, 2026 21:39 JST

Mazda Advances Toward Commercialization of Onboard CO2 Capture System
Jun 09, 2026 00:03 JST

Collaboration Between OCTARVIA Programs and MiPoLin(R)
Jun 08, 2026 23:34 JST

Hitachi joins Anthropic's "Project Glasswing" an AI-powered security program
Jun 08, 2026 23:04 JST
 More Latest Release >>